Denali Therapeutics Inc.

Dr. Douglas G. Cole, MD, is an Independent Director at Sana Biotechnology, Inc., a Chairman at Foghorn Therapeutics, Inc., an Independent Director at Denali Therapeutics, Inc., a Chairman at Sigilon Therapeutics, Inc., a Managing Partner at Flagship Pioneering and a Member at The Phi Beta Kappa Society. He is on the Board of Directors at Sana Biotechnology, Inc., Torque Therapeutics, Inc., Denali Therapeutics, Inc., Inzen Therapeutics, Inc., Repertoire Immune Medicines, Inc., Spinal Muscular Atrophy Foundation, TARIS BioMedical LLC and Birch Rock Camp. Dr. Cole was previously employed as an Independent Director by Editas Medicine, Inc., a Co-Founder by ModernaTX, Inc., an Independent Director by Receptos, Inc., an Independent Director by Quanterix Corp., an Independent Director by Tetraphase Pharmaceuticals, Inc., an Independent Director by AVEO Pharmaceuticals, Inc., a Program Executive by Vertex Pharmaceuticals, Inc., a Medical Director by CytoTherapuetics, Inc., a Member by Alpha Omega Alpha Honor Medical Society, a Principal by Hypnion, Inc., a Principal by Renovis, Inc., and a Principal by Selventa, Inc. He also served on the board at Agios Pharmaceuticals, Inc., Ensemble Therapeutics Corp., Avedro, Inc., Apoptos, Inc., CombinatoRx, Inc., Concert Pharmaceuticals, Inc., Gilead Connecticut, Inc., KSQ Therapeutics, Inc., Moderna, Inc., Morphotek, Inc., Permeon Biologics, Inc., Resolvyx Pharmaceuticals, Inc., Selecta Biosciences, Inc., Seventh Sense Biosystems, Inc., Syros Pharmaceuticals, Inc. and Zalicus, Inc. He received his undergraduate degree from Dartmouth College, a doctorate degree from Perelman School of Medicine and a doctorate degree from the University of Pennsylvania Medical Center.